Using mitochondrial DNA in blood to monitor liver cancer recurrence

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the effectiveness of circulating tumor mitochondrial DNA (ct-mtDNA) as a biomarker for assessing minimal residual disease (MRD) and monitoring recurrence in patients with hepatocellular carcinoma (HCC). Conducted at Tongji Hospital in Wuhan, China, the study will collect and analyze plasma samples from HCC patients to detect mitochondrial mutations before and after treatment. The primary goal is to determine how MRD status impacts progression-free survival, while secondary objectives include examining the correlation between MRD markers and treatment outcomes. The study hypothesizes that ct-mtDNA dynamics are linked to recurrence risk and overall survival in HCC patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with hepatocellular carcinoma (HCC);
* Diagnosis of HCC is according to the American Association for the Study of Liver Diseases or European Association for the Study of the Liver guidelines of HCC management;
* At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or mRESIST criteria.;
* Expected survival time of 12 weeks or more;
* Signed informed consent form and ability to comply with the study visits and related procedures as stipulated in the protocol.

Exclusion Criteria:

* Patients with other active tumors or severe complications;
* Insufficient tumor tissue for MRD detection.

Where it's running

• Tongji Hospital
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Ze-yang Ding, M.D.
• Email: zyding@tjh.tjmu.edu.cn
• Phone: +8613407156200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer

  This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.

  Recruiting Phase 2 Samsung Medical Center · Seoul · NCT07884877

• AI-guided treatment choices for advanced liver cancer

  Researchers are testing an AI tool to help predict which patients with advanced hepatocellular carcinoma will respond to modern systemic therapies.

  Recruiting at 5 sites Universitaire Ziekenhuizen KU Leuven · Anderlecht and 4 other locations · NCT07863258

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

• Biomarker testing to predict treatment response and recurrence in liver cancer

  This study tests biomarkers in adults with hepatocellular carcinoma to see if they can predict how well treatments work and the chance of the cancer coming back.

  Recruiting Tianjin Medical University Cancer Institute and Hospital · Tianjin · NCT07840092

• MRI plus diffusion and CEST imaging to map liver cancer and its immune environment

  This study tests whether adding an extra MRI sequence can help see how the liver cancer microenvironment changes and relate those changes to immune activity in patients with hepatocellular carcinoma.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07838415

• Irreversible Electroporation Added to Targeted Therapy and Immunotherapy for Advanced HCC

  This study tests whether adding irreversible electroporation to lenvatinib and sintilimab can help patients with unresectable advanced hepatocellular carcinoma see bigger tumor shrinkage and become eligible for surgery.

  Recruiting Phase 2 Peking Union Medical College Hospital · Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, China · NCT07832006

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.